Device Trial Radar · NCT07817147
CREO - Microwave Ablation Feasibility Study
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Feb 19, 2026
Primary completion
Feb 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Banner HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Creo Medical Limited; CreoMed, Inc.
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
Conditions
- Pancreatic Cancer
- Liver Cancer (Locally Advanced or Metastatic)
- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Stage III
- Pancreatic Cancer Stage IV
- Liver Cancer Stage IV
- Liver Cancer Stage IIIa
- Liver Cancer Stage IIIb
- Liver Cancer Stage IIIc
Interventions
EUS-Guided MWA DeviceDevice
The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the success of energy delivery during treatment with the deviceTime frame: From first MWA procedure to the end of treatment at Week 5 or 9
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center and Gateway Hospital
Gilbert, Arizona · Recruiting
Cedars Sinai
Los Angeles, California · Not yet recruiting
Rush University Medical Center
Chicago, Illinois · Not yet recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.